 Connection
Heather Moore to Neoplasm Metastasis
This is a "connection" page, showing publications Heather Moore has written about Neoplasm Metastasis.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.227 |
|
|
|
-
Liang J, Ong C, Heslop K, Guan J, Kameswaran V, Daniel B, Shi M, Liang Y, Giltnane JM, Aimi J, Chang CW, Gates MR, Eng-Wong J, Perez-Moreno P, Jhaveri KL, Turner NC, Lim E, Metcalfe C, Moore HM. Loss of luminal lineage drives resistance to next-generation ERa antagonists in pretreated ER+ HER2- locally-advanced or metastatic breast cancer. Nat Commun. 2026 Apr 01; 17(1).
Score: 0.196
-
Abramson VG, Oliveira M, Cervantes A, Wildiers H, Patel MR, Bauer TM, Bedard PL, Becerra C, Richey S, Wei MC, Reyner E, Bond J, Cui N, Wilson TR, Moore HM, Saura C, Krop IE. A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer. Breast Cancer Res Treat. 2019 Nov; 178(1):121-133.
Score: 0.031
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|